Public Interest in Population Genetic Screening for Cancer Risk

An emerging role for DNA sequencing is to identify people at risk for an inherited cancer syndrome in order to prevent or ameliorate the manifestation of symptoms. Two cancer syndromes, Hereditary Breast and Ovarian Cancer and Lynch Syndrome meet the “Tier 1” evidence threshold established by the Centers for Disease Control and Prevention (CDC) for routine testing of patients with a personal or family history of cancer. Advancements in genomic medicine have accelerated public health pilot programs for these highly medically actionable conditions. In this brief report, we provide descriptive statistics from a survey of 746 US respondents from a Qualtrics panel about the public’s awareness of genetic testing, interest in learning about their cancer risk, and likelihood of participating in a population genetic screening (PGS) test. Approximately of half the respondents were aware of genetic testing for inherited cancer risk (n = 377/745, 50.6%) and would choose to learn about their cancer risk (n-309/635, 48.7%). Characteristics of those interested in learning about their cancer risk differed by educational attainment, age, income, insurance status, having a primary care doctor, being aware of genetic testing, and likelihood of sharing information with family (p < 0.05). A sizeable majority of the respondents who were interested in about learning their cancer risk also said that they were likely to participate in a PGS test that involved a clinical appointment and blood draw, but no out-of-pocket cost (n = 255/309, 82.5%). Reasons for not wanting to participate included not finding test results interesting or important, concerns about costs, and feeling afraid to know the results. Overall, our results suggest that engaging and educating the general population about the benefits of learning about an inherited cancer predisposition may be an important strategy to address recruitment barriers to PGS.

[1]  Megan C. Roberts,et al.  Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review , 2022, Frontiers in Genetics.

[2]  Jennifer M. Taber,et al.  Information Avoidance, Self-affirmation, and Intentions to Receive Genomic Sequencing Results Among Members of an African Descent Cohort. , 2021, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[3]  Lora J. H. Bean,et al.  DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[4]  D. L. Doyle,et al.  DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[5]  R. Green,et al.  Precision Population Medicine in Primary Care: The Sanford Chip Experience , 2021, Frontiers in Genetics.

[6]  M. Winget,et al.  Implementation outcomes of Humanwide: integrated precision health in team-based family practice primary care , 2021, BMC Family Practice.

[7]  G. Barsh,et al.  A state-based approach to genomics for rare disease and population screening , 2020, Genetics in Medicine.

[8]  A. Phillippy,et al.  Strategic vision for improving human health at The Forefront of Genomics , 2020, Nature.

[9]  M. Frey,et al.  Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center , 2020, Journal of General Internal Medicine.

[10]  Kim Brown,et al.  Public perception of predictive cancer genetic testing and research in Oregon , 2020, Journal of genetic counseling.

[11]  Tamara S. Roman,et al.  Genomic Sequencing for Newborn Screening: Results of the NC NEXUS Project. , 2020, American journal of human genetics.

[12]  M. Thomson,et al.  A Tale of Two Diverse Qualtrics Samples: Information for Online Survey Researchers , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[13]  M. Khoury,et al.  DNA-Based Population Screening: Potential Suitability and Important Knowledge Gaps. , 2019, JAMA.

[14]  Christine Y. Lu,et al.  Genomic testing is best integrated into clinical practice when it is actionable. , 2019, Personalized medicine.

[15]  V. Sheppard,et al.  Awareness and acceptability of population-based screening for pathogenic BRCA variants: Do race and ethnicity matter? , 2019, Gynecologic oncology.

[16]  J. Berg,et al.  An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening. , 2019, The Journal of pediatrics.

[17]  J. McNeil,et al.  Correction: Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis , 2019, Genetics in Medicine.

[18]  Ebony B. Madden,et al.  IGNITE network: Response of patients to genomic medicine interventions , 2019, Molecular genetics & genomic medicine.

[19]  Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey , 2019, Journal of Community Genetics.

[20]  K. Ormond,et al.  Genetic Counselors’ and Genetic Counseling Students’ Implicit and Explicit Attitudes toward Homosexuality , 2019, Journal of Genetic Counseling.

[21]  R. Green,et al.  Correction: A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health , 2018, PLoS medicine.

[22]  V. S. Gordeev,et al.  Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women , 2018, Journal of the National Cancer Institute.

[23]  Matthew R. Schwartz,et al.  Interest and Uptake of MC1R Testing for Melanoma Risk in a Diverse Primary Care Population: A Randomized Clinical Trial , 2018, JAMA dermatology.

[24]  Christopher P. Childers,et al.  National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer , 2018, JAMA oncology.

[25]  Nate C. Apathy,et al.  Trends and Gaps in Awareness of Direct-to-Consumer Genetic Tests From 2007 to 2014. , 2018, American journal of preventive medicine.

[26]  M. Khoury,et al.  Evaluating the role of public health in implementation of genomics-related recommendations: a case study in hereditary cancers using the CDC Science Impact Framework , 2018, Genetics in Medicine.

[27]  Jiang Bian,et al.  Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing , 2018, BMC Public Health.

[28]  S. Buys,et al.  Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[29]  Anne Lanceley,et al.  Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review , 2017, BMC Public Health.

[30]  Kimberly M. Kelly,et al.  Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations , 2017, Journal of health communication.

[31]  Sheri D Schully,et al.  A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.

[32]  G. Henderson,et al.  The Promise and Peril of Genomic Screening in the General Population , 2015, Genetics in Medicine.

[33]  J. Berg,et al.  A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing , 2015, Genetics in Medicine.

[34]  Erika A. Waters,et al.  Public Awareness of Direct-to-Consumer Genetic Tests: Findings from the 2013 U.S. Health Information National Trends Survey , 2015, Journal of Cancer Education.

[35]  Heidi L Rehm,et al.  Return of genomic results to research participants: the floor, the ceiling, and the choices in between. , 2014, American journal of human genetics.

[36]  A. Olshan,et al.  We screen newborns, don’t we?: realizing the promise of public health genomics , 2013, Genetics in Medicine.

[37]  M. Putt,et al.  Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. , 2005, JAMA.

[38]  Jane Wardle,et al.  Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. , 2004, Preventive medicine.

[39]  Diane C. Tucker,et al.  Knowledge About Genetic Risk for Breast Cancer and Perceptions of Genetic Testing in a Sociodemographically Diverse Sample , 2000, Journal of Behavioral Medicine.

[40]  I. Ajzen The theory of planned behavior , 1991 .